Global Tuberculosis Drugs Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024
The Global Tuberculosis Drugs Market is expected to grow progressive from USD 1,046 million in 2017 to USD 1,432 million in 2024 at a progressing CAGR of 4.6% during the forecast period.
Factor driving the market are increasing number of TB patients, rising awareness among people, and growing number of research and development activities in novel drug development. Moreover, technological advancement in early stage detection, and government and non government organizations initiatives to promote TB drugs are further augmenting the growth of the market. The years used for the assessment are as follows:
Historical year: 2014, 2015 and 2016
Base year: 2017
Forecast period: 2018 – 2024
The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;
Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
Interacting with key opinion leaders of the market and developing data points based on interaction with them
Study of past trends in the market and their year on year Impact on the market size and share
Analyzing the collected data points
Bridging the data points to calculate the total global tuberculosis drugs market and its various segments
Anticipating potential risks
Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global tuberculosis drugs market
Finalizing the overall size and share of the global tuberculosis drugs market
To analyze market trends, opportunities, drivers, and restraints associated with the global tuberculosis drugs market
To study market response with respect to the mergers and acquisitions in the industry
To profile key companies operating in the global tuberculosis drugs market and provide their competitive landscape
The research scope for Global Tuberculosis Drugs Market is as follows:
By Drugs Class
First-line anti-TB drugs
Second-line anti-TB drugs
By Distribution Channel
Middle East and Africa
The global tuberculosis drugs market was estimated at USD 1,046 million in 2017 and is expected to reach USD 1,432 million in 2024 at a CAGR of 4.6% during the forecast period. Factor driving the market are increasing number of TB patients, rising awareness among people, and growing number of research and development activities in novel drug development. Moreover, technological advancement in early stage detection, and government & non government organization initiatives to promote TB drugs are further augmenting the growth of the market.
Tuberculosis (TB) is caused by the Mycobacterium tuberculosis bacteria and is highly contagious disease. TB is caused by inhaling tuberculosis bacilli in the air. According to the World Health Organization (WHO), in 2016, about 10.4 million people across the globe became infected with TB. In developing countries, tuberculosis remains a significant cause of both illness and death. The rise in TB drugs in developing countries is due to growing number of patients diagnosed with TB, as well as rising awareness among people about its treatment.
The U.S. Agency for International Development (USAID) support diagnosis and treatment services for millions of people which are affected by TB and multidrug resistance tuberculosis. Asia-Pacific holds the maximum share of the market, owing to growing number of TB patients in countries such as, Philippines, Nigeria, Indonesia, South Africa, Pakistan, and China.